Ecotoxicology and Environmental Safety
January 31, 2024
Sen Zhao, Jinyuan Chen, Chenhao Zhong et al.
3 citations
5-MeO-MiPT, a novel psychoactive tryptamine, caused inhibited movement and anxiety-like behavior in adult zebrafish. Metabolomic analysis after drug injection revealed 22 distinct potential biomarkers and seven significantly altered metabolic pathways, including amino acid, lipid, and energy metabolism. The metabolic changes indicated observable brain damage, especially disruption in the liver-brain pathway, linking the drug's metabolic effects to the anxiety-like behavior.
Journal of pharmaceutical and biomedical analysis
April 15, 2024
Yanjiao Wang, Chenhao Zhong, Jinyuan Chen et al.
5-MeO-MiPT is metabolized through multiple phase I and II pathways in both zebrafish and human liver microsomes. In zebrafish, six metabolites were identified, with N-Demethylation and Indole-hydroxylation as primary phase I reactions, and Glucoside conjugation and Sulfonation as phase II reactions. In human liver microsomes, nine metabolites were generated, including N-Demethylation, 5-O-Demethylation, N-Depropylation, N-Oxidation, Indole-hydroxylation, and combined reactions. Phase II metabolism in human microsomes involved Glucoside conjugation after Indole-hydroxylation or 5-O-Demethylation. Proposed markers for screening 5-MeO-MiPT intake include 5-MeO-MiPT-N-Demethylation, 5-MeO-MiPT-Indole-hydroxylation, and OH&Glucoside conjugation-5-MeO-MiPT, along with the parent drug.